Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 7/20 | 0.51 |
| ▸ | AKR1C2 | P52895 | 7/20 | 0.51 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | METAP1 | P53582 | 1/20 | 0.42 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.40 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NQO2 | P16083 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3859853 | 0.83 | PTGS2 (0.48) | AKR1C3AKR1C2PTGS1METAP1GAA | |
| SCHEMBL7409039 | 0.82 | FFAR1 (0.44) | AKR1C3AKR1C2AKR1C1PTGS1METAP1 | |
| SCHEMBL11811157 | 0.80 | ALDH1A1 (0.43) | AKR1C3AKR1C2PTGS1METAP1GAA | |
| SCHEMBL3869414 | 0.80 | METAP1 (0.42) | METAP1GAAL3MBTL1ALDH1A1MEN1 | |
| SCHEMBL7409036 | 0.78 | PPARG (0.42) | AKR1C3AKR1C2AKR1C1PTGS1METAP1 | |
| SCHEMBL6936252 | 0.76 | METAP1 (0.43) | AKR1C3AKR1C2PTGS1METAP1GAA | |
| SCHEMBL7100367 | 0.73 | AKR1C2 (0.47) | AKR1C3AKR1C2PTGS1METAP1GAA | |
| SCHEMBL10607263 | 0.73 | HTR2C (0.42) | METAP1GAAL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL11813130 | 0.72 | METAP1 (0.50) | METAP1GAAL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL11809120 | 0.72 | L3MBTL1 (0.40) | AKR1C3AKR1C2L3MBTL1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020107248-A1 | Method for treating patients with neoplasia by administering substituted sulfonyl indenyl acetic and propionic acids and esters thereof | OSI PHARMACEUTICALS, INC. | 2002-08-08 | — | — | US | disclosed |
| US-6403831-B1 | 5,6-DIFLUORO-2-METHYL-1-(3,4,5-TRIMETHOXY-BENZYLIDENE)-3-(N-BE NZYL)-INDENYL ACETAMIDE; ANTITUMOR AND ANTICARCINOGENIC AGENT USED TO TREAT PRECANCEROUS LESIONS | CELL PATHWAYS, INC. | 2002-06-11 | — | — | US | disclosed |
| US-6028116-A | Substituted condensation products of 1H-indenyl-hydroxyalkanes with aldehydes for neoplasia | CELL PATHWAYS, INC. (US) | 2000-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107248-A1 | Method for treating patients with neoplasia by administering substituted sulfonyl indenyl acetic and propionic acids and esters thereof | VHL, IDH3A, GLI2 | AKR1C3 170/4885AKR1C2 143/4885AKR1C1 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.